Pharmacovigilance Experts are key players in the pharmaceutical industry, tasked with ensuring the ongoing safety and effectiveness of medicines. Their main role involves collecting, analyzing, and interpreting data related to adverse drug reactions (ADRs), helping to identify new risks or confirm known ones. These experts monitor both clinical trial data and post-marketing reports to detect safety signals early and prevent harm to patients. They prepare detailed safety reports, manage regulatory submissions, and maintain compliance with international pharmacovigilance regulations such as those from the FDA, EMA, and ICH.
These professionals possess strong analytical, communication, and decision-making skills, which are essential for assessing complex safety data and making informed recommendations. They work closely with regulatory teams, medical affairs, and research and development departments to ensure all safety concerns are addressed appropriately. With the growing volume of real-world data and digital health records, their role is evolving to include advanced data analytics and AI tools. As new therapies—especially biologics and personalized medicines—enter the market, their role becomes even more critical. Pharmacovigilance experts help guide decisions that can lead to label updates, safety warnings, or even product withdrawal when needed. By identifying patterns in adverse event reports and applying medical judgment, they help reduce risks and ensure that the benefits of a drug continue to outweigh its risks. Their work protects both patients and public health on a global scale.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Genetic keys and nano locks: Unlocking personalized medicine
Srividya Narayanan, Northeastern University, United States
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico